Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 11/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13622632 | 0.92 | LMNA (0.47) | FFAR4MEN1KMT2ALMNAHTT | |
| SCHEMBL4354310 | 0.82 | MEN1 (0.40) | MEN1NPC1RAB9AKMT2AHSP90AA1 | |
| Trifluoroacetic Acid SCHEMBL1026901 | 0.80 | FFAR4 (0.51) | FFAR4 | |
| Trifluoroacetic Acid SCHEMBL1026170 | 0.80 | FFAR4 (0.59) | FFAR4CYP3A4TACR1 | |
| SCHEMBL20249464 | 0.80 | LMNA (0.43) | FFAR4MEN1KMT2ALMNAHTT | |
| Trifluoroacetic Acid SCHEMBL1025564 | 0.78 | FFAR4 (0.44) | FFAR4CYP3A4TACR1 | |
| SCHEMBL20038408 | 0.78 | LMNA (0.46) | FFAR4MEN1KMT2ALMNAHTT | |
| Trifluoroacetic Acid SCHEMBL1024329 | 0.78 | ALDH1A1 (0.55) | FFAR4CYP3A4 | |
| SCHEMBL1728820 | 0.77 | SCD (0.49) | LMNAHTT | |
| Trifluoroacetic Acid SCHEMBL1025547 | 0.77 | FFAR1 (0.50) | FFAR4HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | FFAR4 2075/4885MEN1 1321/4885NPC1 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.